These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 37652000)

  • 1. Adapting psychedelic medicine for headache and chronic pain disorders.
    Schindler EAD; Hendricks PS
    Expert Rev Neurother; 2023; 23(10):867-882. PubMed ID: 37652000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychedelics in the Treatment of Headache and Chronic Pain Disorders.
    Schindler EAD
    Curr Top Behav Neurosci; 2022; 56():261-285. PubMed ID: 35546382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychedelics as preventive treatment in headache and chronic pain disorders.
    Schindler EAD
    Neuropharmacology; 2022 Sep; 215():109166. PubMed ID: 35718005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are psychedelics the answer to chronic pain: A review of current literature.
    Kooijman NI; Willegers T; Reuser A; Mulleners WM; Kramers C; Vissers KCP; van der Wal SEI
    Pain Pract; 2023 Apr; 23(4):447-458. PubMed ID: 36597700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knowledge, Perceptions, and Use of Psychedelics among Individuals with Fibromyalgia.
    Glynos NG; Pierce J; Davis AK; McAfee J; Boehnke KF
    J Psychoactive Drugs; 2023; 55(1):73-84. PubMed ID: 35001856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LSD and psilocybin for chronic nociplastic pain: A narrative review of the literature supporting the use of classic psychedelic agents in chronic pain.
    Van Der Walt J; Parker R
    S Afr Med J; 2023 Nov; 113(11):22-26. PubMed ID: 38525640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.
    Kelly DF; Heinzerling K; Sharma A; Gowrinathan S; Sergi K; Mallari RJ
    Neurosurgery; 2023 Apr; 92(4):680-694. PubMed ID: 36512813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosing Psychedelics and MDMA.
    Liechti ME; Holze F
    Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychedelic therapy in depression and substance use disorders.
    Korkmaz ND; Cikrikcili U; Akan M; Yucesan E
    Eur J Neurosci; 2024 Jul; 60(2):4063-4077. PubMed ID: 38773750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.
    Zia FZ; Baumann MH; Belouin SJ; Dworkin RH; Ghauri MH; Hendricks PS; Henningfield JE; Lanier RK; Ross S; Berger A
    Neuropharmacology; 2023 Aug; 233():109528. PubMed ID: 37015315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular insights into psychedelic drug action.
    Slocum ST; DiBerto JF; Roth BL
    J Neurochem; 2022 Jul; 162(1):24-38. PubMed ID: 34797943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.